Literature DB >> 26525378

[Treatment of haemophilia in Austria].

Ingrid Pabinger1, Max Heistinger2, Wolfgang Muntean3, Sylvia-Elisabeth Reitter-Pfoertner4, Sabine Rosenlechner5, Thomas Schindl6, Gerhard Schuster7, Werner Streif8, Katharina Thom9, Christoph Male9.   

Abstract

This guideline which is endorsed by the Austrian Society of Haemophilia, the Austrian Society of Paediatrics, and the Austrian Society of Haematology & Medical Oncology is intended to give a clear and practical guidance for diagnosing and treating haemophilia in Austria. In the treatment of haemophilia there are few controlled interventional trials, and recommendations usually have a rather low level of evidence.The main basis for this paper are the new international guidelines by the World Federation of Hemophilia, published in 2013. These were adapted according to the local situation and experience.Covered topics are diagnostics, control visits, pharmacological treatment options, prophylaxis and treatment in children and adults, possible problems arising in haemophilia carriers and special aspects like home therapy, options for venous catheters, management of various traumas, bleedings and interventions, including dental procedures, and last not least inhibitors and their treatment.

Entities:  

Keywords:  Clotting factor concentrates; Desmopressin; Guidelines; Haemophilia

Mesh:

Substances:

Year:  2015        PMID: 26525378     DOI: 10.1007/s00508-015-0872-x

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  51 in total

1.  [The importance of preanalytics for the coagulation laboratory].

Authors:  Georg Endler; G Slavka; T Perkmann; A Haushofer
Journal:  Hamostaseologie       Date:  2010-05       Impact factor: 1.778

Review 2.  Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.

Authors:  Antonio Coppola; Annarita Tagliaferri; Mirko Di Capua; Massimo Franchini
Journal:  Semin Thromb Hemost       Date:  2012-02-07       Impact factor: 4.180

Review 3.  Hemophilia emergencies.

Authors:  M T Bush; N Roy
Journal:  J Emerg Nurs       Date:  1995-12       Impact factor: 1.836

4.  Definitions in hemophilia: communication from the SSC of the ISTH.

Authors:  V S Blanchette; N S Key; L R Ljung; M J Manco-Johnson; H M van den Berg; A Srivastava
Journal:  J Thromb Haemost       Date:  2014-09-03       Impact factor: 5.824

5.  Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group.

Authors:  M Hilgartner; L Aledort; A Andes; J Gill
Journal:  Transfusion       Date:  1990-09       Impact factor: 3.157

6.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Authors:  Jan Astermark; Sharyne M Donfield; Donna M DiMichele; Alessandro Gringeri; Steven A Gilbert; Jennifer Waters; Erik Berntorp
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

7.  Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Authors:  T C Abshire; H H Brackmann; I Scharrer; K Hoots; C Gazengel; J S Powell; E Gorina; E Kellermann; E Vosburgh
Journal:  Thromb Haemost       Date:  2000-06       Impact factor: 5.249

8.  [Immune tolerance therapy for inhibitors in haemophilia A].

Authors:  J Oldenburg
Journal:  Hamostaseologie       Date:  2008-10       Impact factor: 1.778

9.  Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.

Authors:  P L F Giangrande; J T Wilde; B Madan; C A Ludlam; E G D Tuddenham; N J Goddard; G Dolan; J Ingerslev
Journal:  Haemophilia       Date:  2009-02-01       Impact factor: 4.287

10.  A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.

Authors:  L M Aledort; R H Haschmeyer; H Pettersson
Journal:  J Intern Med       Date:  1994-10       Impact factor: 8.989

View more
  3 in total

1.  Establishing an online physical exercise program for people with hemophilia.

Authors:  Barbara Wagner; Axel Seuser; Steffen Krüger; Marie Luca Herzig; Thomas Hilberg; Cihan Ay; Timothy Hasenöhrl; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2019-09-18       Impact factor: 1.704

2.  Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria.

Authors:  Cihan Ay; Clemens Feistritzer; Joachim Rettl; Gerhard Schuster; Anna Vavrovsky; Leonard Perschy; Ingrid Pabinger
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

Review 3.  Pain management in hemophilia: expert recommendations.

Authors:  Waltraud Stromer; Ingrid Pabinger; Cihan Ay; Richard Crevenna; Josef Donnerer; Clemens Feistritzer; Sophie Hemberger; Rudolf Likar; Florian Sevelda; Katharina Thom; Barbara Wagner; Werner Streif
Journal:  Wien Klin Wochenschr       Date:  2021-03-04       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.